MedTrace Logo

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

NCT00820794 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-03-05

No results posted yet for this study

Summary

The purpose of this study is to investigate if PD 0332334 affects the pharmacokinetics of lithium by co-administering both drugs to healthy adults.

Conditions

  • Generalized Anxiety Disease

Interventions

DRUG

Lithium

300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment

DRUG

PD 0332334

225 mg q12h PD 0332334, oral, 9 days treatment

DRUG

Lithium

300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout

DRUG

PD 0332334

225 mg q12h PD 0332334, oral, 9 days treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-06-30
Completion
2009-06-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820794 on ClinicalTrials.gov